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Abstract 
Prostate cancer (PC) is a common malignancy among elderly males and is non-curable once 
it becomes metastatic. In recent years, a number of antigen delivery systems have emerged 
as a viable and promising immunotherapeutic agents against PC. The approval of Sipuleucel-
T by the US FDA for the treatment of males with asymptomatic or minimally symptomatic 
castrate resistant PC was a landmark in cancer immunotherapy, making this the first 
approved immunotherapeutic. A number of vaccines are under clinical investigation, each 
having its own set of advantages and disadvantages. Here, we discuss the basic technologies 
underlying these different delivery modes, we discuss the completed and current human 
clinical trials, as well as the use of vaccines in combination with immune checkpoint 
inhibitors. 
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Background 
Prostate cancer (PC) is the second most commonly diagnosed malignant tumor in men and a 
major cause of mortality, with an estimated 385,560 deaths globally expected by 2020 [1]. 
In 2016, prostate cancer was the 3rd most common cause of cancer deaths in Australia and 
the 2nd most common cause of cancer deaths amongst males [2]. In a systematic review of 
over 71,000 PC patients 10–20 % of the cases progressed to castration-resistant prostate 
cancer (CRPC), for which there is no effective cure [3]. The vast majority (> 80 %) of patients 
diagnosed with CRPC already have distant metastases and, one third of the remaining 
subjects are likely to develop metastases within 2 years [4, 5]. This was also shown recently, 
based on the Danish PC registry where 19,487 males with PC had died in the 18 year period 
(1995-2013), the majority of those who had died were those who had lymph node and 
elsewhere metastasis at the time of diagnosis. This was supported by a decreased number 
of cases of metastatic disease at the time of diagnosis over time which correlated with 
overall increased median survival [6]. The current standard chemotherapeutic treatment 
regime for patients with CRPC is based on docetaxel plus prednisone. This approach only 
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modestly enhances patient survival and, as with most chemotherapeutics, a range of 
undesirable side effects ensues [7]. Other novel treatment options include radium-223 and 
androgen receptor targeted therapy for CRPC which has shown to improve survival 
compared to placebo [8, 9]. However, there is a need for less toxic alternative treatments, 
such as, active immunotherapy. PC is a viable candidate for the development of an 
immunotherapeutic or vaccine, as current standard treatments for the clinical management 
of CRPC are inadequate., PC cells express an array of tissue specific proteins that could act 
as therapeutic targets, including prostate-specific antigen (PSA) and prostatic acid 
phosphatase (PAP) [3]. In the last decade, a number of vaccines against PC (i.e., virus based, 
gene based, peptide/protein based and cell based vaccines) have been developed and 
tested in pre-clinical models and in human clinical trials for safety and therapeutic profile 
[10-12]. 
 Tumor development and progression results from a cancer-induced 
immunosuppressive state, in which the patient’s immune system is not able to recognize 
and destroy cancer cells (cancer immunoediting), hence, escaping immune surveillance. 
Therefore, immune evasion is recognized as a hallmark feature of cancer and, in the last 5 
years, immune checkpoints have surfaced as key players. As a result, much interest in 
anticancer research is aimed at blocking immune checkpoints alone or in combination with 
immunotherapeutic agents/vaccines to restore and enhance cellular-mediated antitumor 
immunity and achieve durable tumor regression [13].  
 Herein, we describe the current knowledge regarding various types of 
immunotherapeutic/vaccine strategies along with human clinical trial outcomes. In addition, 
we present the effects and importance of immune checkpoint inhibitors mediating cancer 
regression.  
 
Vaccine approach: developments in preclinical studies 
Prior to potential vaccines entering human clinical trials, it is important to determine its 
immune efficacy using in vitro studies and in vivo animal models. Many prospective vaccines 
will not progress beyond this stage due to unacceptable adverse reactions in animal models 
or a lack of immunogenicity. However, careful pre-clinical analysis is required, despite over 
the decades of development of cellular therapies, mouse models have produced often 
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contradictory and conflicting results. Hence, comprehensive and convincing pre-clinical data 
(to include appropriate animal models, use of humanized mouse models, appropriate 
immune cell analysis etc.) is a major pre-requisite prior to moving into human trials. 
Pharmacological and toxicology studies of new vaccines must also be assessed prior to 
clinical development. The goals of preclinical safety evaluation include single-dose toxicity; 
repeated-dose toxicity; primary pharmacodynamics (immunogenicity); secondary 
pharmacodynamics (safety); pharmacokinetics and local tolerance. For the in vivo phase of 
preclinical testing, selection of the relevant animal species, age of test animals, their 
physiological state, vaccine delivery (including dose, route of administration and treatment 
regimen) and stability of the test material under the conditions of use are necessary 
regulatory requirements prior to human clinical studies.  
 
Viral vector-based approach 
Viral vectors are attractive for use in cancer immunotherapy as they mimic natural infection 
and lead to the induction of robust immune responses. The advantage of viral vectors is 
their immunogenicity, and the off-the-shelf nature of the ensuing construct, which does not 
need to be individualized for each patient. The major disadvantage of a viral vaccine 
construct is the complex nature of its backbone, which means that the majority of the 
immune response is targeted against the virus itself, rather than the target antigen. To 
circumvent these limitations, significant innovations have been implemented [14], such as,  
immunogenicity of the standard vaccinia virus vector is dramatically improved by the 
addition of 3 immunomodulatory proteins (LFA-1, ICAM and B7-1) [15]. Preclinical studies 
showed that this combination was strikingly synergistic in terms of generating robust 
immune responses, and the technology was adapted for clinical development. Modification 
could utilize heterologous prime boost regimens that prime the immune system against a 
target antigen and subsequently boosting antigen-specific immune responses with a distinct 
antigen, provided another viral backbone was employed.  
 One of the earliest vaccines for prostate cancer was GVAX®, which at the time used 
the Dunning R3327 rat model of human PC. The high grade and metastatic subline MAT-
LyLu transduced with a retroviral vector carrying the gene for granulocyte macrophage-
colony stimulating factor (GM-CSF), was used to immunize tumor-bearing rats, and showed 
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that one third of the treated rats were tumor free. This approach was translated into human 
clinical trials, first using GM-CSF-secreting, irradiated autologous patient prostate tumor 
cells [16] and later followed by allogeneic tumor cells, also engineered to secrete GM-CSF 
[17].  
 Furthermore, the uses of vaccinia viral vectors and adenovirus (Ad) vectors have 
shown promise in preclinical studies [18-21]. Vaccinia viral vectors have been used both as  
replication competent vaccine strains [22] and a modified, limited replication variant [19], 
whilst all of the Ad based vaccines are based on the replication deficient strain [21]. 
Preclinical studies conducted with vaccinia virus vector carrying the gene encoding for 
human PSA induces strong CD8+ T cells in mice [23, 24], and shown to have a safety profile 
in monkeys [25]. On the other hand, Ad vectors have been shown to be more immunogenic 
compared to vaccinia virus vectors. However, a major challenge to Ad-based vaccines is the 
presence of pre-existing neutralizing antibodies resulting from prior environmental 
exposure, which can neutralize adenoviruses prior to activation of immune responses. In 
animal models, the use of replication-deficient Ad serotype 5 vector (Ad5), transduced with 
the full-length human PSA (Ad5-PSA) [26-28] stimulates strong anti-PSA antibody and CD8+ 
T cell immune responses which lyze RM11/PSA+ tumor cells in mice [29]. On the other hand, 
in established tumor studies, the effectiveness of such vaccine was only noted in 20 % of 
mice which was enhanced to 80 % when combined with cytokine genes (IL-2, IL-12, TNF-α) 
[29]. Interestingly, incorporation of Ad5-PSA in a gelfoam matrix further enhanced antibody 
and CD8+ T cell responses [28]. Ad5-PSA priming in gelfoam matrix also removed the 
inhibitory effects of adenoviral immunity on CD8+ T cell activation in mice naive to PSA but 
immune to Ad. The ability to immunize with Ad vaccines in the presence of anti-Ad 
antibodies has important implications for their use in clinical trials as most males would 
have been exposed to Ad5 viruses and possess significant levels of anti-Ad antibodies. 
Moreover, the combination of Ad5-PSA vaccine with immunostimulatory TLR9 agonist, CpG 
(injected simultaneously, or Ad5-PSA followed by CpG days later), enhances ensuing 
immune responses [26, 27, 30] and protects mice in both prophylactic and therapeutic 
settings [31]. Likewise, Ad5 vector transduced with a truncated gene for prostate specific 
membrane antigen (Ad5-PSMA) and pulsed with mouse dendritic cells (DCs) induces strong 
CD8+ T cell responses and protect against PSMA+ tumors in mice [21]. Thus, the advantage 
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of Ad5 platform is its relative immunogenic potential in preclinical settings, and its 
translation into human clinical trials. 
 
DNA-based approach 
DNA vaccines have emerged as promising approach to antigen delivery based on injection of 
DNA into the host with the aim of transducing cells at the injection site, resulting in the 
subsequent production of immunogenic protein and stimulation of antitumor immune 
responses. The advantage of DNA-based vaccines is the ease of manufacture, yield and 
purity, highly reproducible and cost-effective for large scale up [25, 27]. It has been well 
documented that DNA vaccination is a highly potent strategy for inducing both prophylactic 
and therapeutic responses [23].  
 One of the earliest uses of DNA technology for the development of tumor vaccines 
was reported by Irvine in 1995 [32] and further pursued by Disis et al. in 2003 [33]. 
Preclinical studies have used the prostate tumor-associated antigens PAP, PSA, PSMA and 
prostate stem cell antigen (PSCA) [18, 34, 35]. The experimental plans and antigens used in 
DNA vaccine approaches are varied, with some co-administering of GM-CSF [36] whilst 
others make use of the prime–boost approach [18]. Most studies reported use of DNA that 
encoded for the native protein, whereas Vittes et al. immunized with DNA that encoded for 
different PSMA peptides [35]. Interestingly, the latter study demonstrated that 2/3 of the 
peptides used were able to induce T cell responses and were able to lyze tumor target cells 
that expressed the native protein [35]. Hence, DNA-based vaccines offer a viable alternative 
for the development of PC vaccines. 
 
Cell-based approach 
Dendritic cells (DC) are the most potent antigen presenting cells in initiating adaptive 
immune responses and present an attractive platform for cancer vaccines [37, 38]. The 
source of tumor antigen in such approach is important, and may involve synthetic peptides, 
autologous tumor cell lysates or lysates from cultured cancer cells. Using autologous tumor 
cell lysates is particularly attractive, as ensuing immune responses are directed against the 
antigen repertoire derived from a patient’s own individual tumor. However, autologous cells 
vary greatly in number, viability and recovery, and an adequate surgical sample is required 
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for vaccine to be formulated [39]. The advantages of DC-based vaccine includes the 
presentation of a broad spectrum of antigens, as well as the potential augmentation of the 
immune response conferred by the non-self major histocompatibility complex (MHC) 
molecules present in allogeneic tumor cells [40]. Likewise, the ex vivo maturation step also 
has benefits as it has been shown in cancer patients that DC are deficient in numbers and 
function. Disadvantages include the complexity of manufacture, especially the shipping of 
leukopheresis product to a central processing facility, ex vivo culture for 5-7 days, 
maturation of DCs, pulsing with antigen, and shipping the final product back to the 
treatment center for infusion., The costs involved in such approach are  also extremely high 
[41]  
 DCs pulsed with a number of proteins have been used in vaccine studies and are the 
prototypical cellular vaccines. One of the early DC vaccine was that developed by Heiser et 
al., where DCs were pulsed with PSA RNA and anti-PSA and T-cell responses were induced 
[42]. Furthermore, anti-prostate tumor cytotoxic T cells (CTL) were induced in vitro using DC 
pulsed with RNA extracted from human PC cells [43]. The PC vaccine that has received the 
most publicity and attention is Sipuleucel-T or Provenge®, a cell-based approach. In early 
preclinical studies using rats, immunization with antigen-presenting cells (APCs) pulsed with 
a fusion protein of rat PAP and rat GM-CSF [44] did not show anti-tumor effects although 
normal rat prostate tissues developed lymphocytic infiltrates. Subsequent in vitro studies 
using the Dunning R3327 tumor cells provided support that lymphocytes from APC/fusion 
protein immunized rats could have an antitumor effect [44]. 
 
Progress in human clinical trials 
Clearly, preclinical PC vaccine immunotherapy studies have produced strong foundation for 
the extension of these therapies into human clinical trials and subsequent treatment of men 
with PC. DC, DNA and viral vectors are currently in Phase I-III human clinical trials. The 
identification of prostate tumor-associated antigens and the ability to isolate their genes has 
propelled antigen-specific vaccine immunotherapy into a new era of vaccine development. 
 
Sipuleucel-T (Provenge®) 
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The first autologous cellular immunotherapy approved by the Food and Drug Administration 
(FDA) in 2010 and by the European Medicines Agency (EMA) for the treatment of metastatic 
castrate resistant prostate cancer (mCRPC) was sipuleucel-T (Provenge®).  To date it remains 
the only FDA-approved immunotherapeutic approach for PC, although it should be noted 
that the FDA initially declined its use and a new phase III trial was designed and registered. 
This approval was based on a blinded, randomized controlled trial where those that 
received sipuleucel-T, had a 22 % reduced risk of death compared to the placebo group [14]. 
The reduction represented a 4.1-month improvement in median survival (25.8 months vs. 
21.7 months) and the 3-year survival rate was 31.7 % in the sipuleucel-T group compared 
23.0 % in the placebo group [45].; although only marginal improvements in median survival 
were noted. A recent phase II study (NCT01487863, results obtained March 2017) evaluated 
the impact of concurrent versus sequential administration of abiraterone acetate plus 
prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product 
parameters), and to assess the safety and efficacy of sipuleucel-T administration in patients 
with mCRPC. The cumulative CD54 upregulation ratio between the cohorts was similar in 
both the concurrent and sequential groups [46]. CD54 is an intercellular adhesion molecule 
1 which is expressed by endothelial and leukocyte cells which upon stimulation secrete IL-1 
and tumor necrosis factor. Upregulation of CD54 in PC implies overall survival. Currently the 
NCT00970203 trial is recruiting participants for intradermal immunization of DC-loaded with 
allogeneic PC cell lines in combination with androgen ablation in patients with PC. This is a 
phase II, randomized and open label with cross over intervention study and will assess the 
feasibility, safety and efficacy of the vaccine. The estimated completion date of the study is 
December 2018 [47]. 
 
Tumor-mRNA transfected DC 
A phase I trial using autologous ex vivo monocyte derived DCs transfected with mRNA from 
allogeneic PC cells (LNCaP, DU145 and PC-3) were injected (2 × 107 cells) either intranodally 
or intradermally into patients with mCRPC and were reported to be well tolerated [48]. In 
addition, a decrease in PSA progression in 13/19 patients was noted which correlated to 
increased T cell proliferative responses; clinical outcome was significantly related to immune 
responses [49]. This work has been currently extended in the form of an active Phase I/II 
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trial using autologous tumor cells as an antigen source (NCT01197625) for curative resected 
PC patients, and the primary outcome measure is expected by September 2019 with a 
completion date of September 2025. 
 
GVAX® 
GVAX is composed of both castrate-sensitive and castrate resistant allogeneic PC cell lines 
(LNCaP and PC3, respectively) transduced with GM-CSF [14]. Two phase III human clinical 
trials were conducted which led to their premature discontinuation due to severe adverse 
reactions. In the first study, (VITAL-1) GVAX prostate was compared to standard 
chemotherapy (docetaxel) in males with mCPRC. In the second trial (VITAL-2), the 
combination of GVAX prostate and docetaxel was compared to docetaxel alone; this time a 
more advanced population, males with symptomatic mCRPC, were enrolled; preliminary 
results suggested an imbalance in deaths in the combined treated group [50]. Nevertheless, 
these concerns prompted an unplanned, and slightly underpowered efficacy analysis of the 
VITAL-1 trial [51], which indicated ineffective and led to its premature termination. In 
addition, the combination of GVAX and ipilimumab was studied in an open-labeled, single-
center, phase I clinical trial [52]. Ipilimumab (YevroyTM) is an-anti CTLA-4 monoclonal 
antibody which downregulates the immune system and has been shown in two randomized 
phase III trials to improve the overall survival of patients with metastatic melanoma [52, 53]. 
In a phase I study of 28 patients with mCRPC and no previous history of chemotherapy, 
patients received 13 intradermal injections of GVAX (5 × 108 cells) and escalating doses of 
ipilimumab. At high ipilimumab doses side effects such as, inflammation of pituitary gland 
and/or sarcoid alveolitis developed whereas, at low doses it was generally safe and well 
tolerated. In addition, the combination of GVAX and ipilimumab improved overall survival 
compared to sipuleucel-T or PostVac VF [53, 54]. However, it is not clear whether this 
combined treatment constitutes a significant improvement over GVAX alone in terms of 
overall survival. 
 
PROSTVAC 
In terms of early development, a trial utilizing vaccinia-PSA prime/boost regimen, showed 
that a vaccinia-PSA prime, followed by a series of fowlpox-PSA boosts was more 
 10 
immunogenic then other regimens [55]. A carefully considered series of combination trials 
followed involving chemotherapy, radiation therapy and androgen ablation. Importantly, a 
randomized placebo controlled phase II human clinical trial of PROSTVAC was injected in 
asymptomatic or minimally symptomatic patients with mCRPC [56]. The primary endpoint 
was time to progression, and upon progression patients were treated at their physicians’ 
discretion – no crossover was permitted. Even though the primary endpoint was not met, 
long term follow-up showed a statistically significant improvement in overall survival of the 
ProstVac group compared to control (25.1 months versus 16.6 months).  
 Furthermore, in a single arm phase II trial of PSA-TRICOM [PROSTVAC expressing PSA 
together with 3 immune-stimulating molecules (ICAM-1, B7.1 and LFA-3 by poxviral vectors 
and boosted using fowlpox vectors)], in 32 patients with mCRPC showed an improved 
survival. The improved survival correlated to a 2-fold increase in PSA specific IFN-gamma 
secreting T cells [57]. A randomized phase II trial (NCT01145508) using docetaxel with or 
without PSA-TRICOM vaccine in patients with mCRCP was conducted  [58]. to assess the  
overall survival; however, the study outcome remains inclusive as an insufficient number of 
participants were enrolled in the study. A phase III randomized double blind study is 
currently in progress in order to determine the efficacy of PROSTVAC alone or in 
combination with GM-CSF in prolonging the overall survival in males with few or no 
symptoms from mCRPC; the trial is estimated to be completed by June, 2018 [59]. In 
general, PROSTVAC is well tolerated with common side effects being, reactions at the site of 
injection, fatigue, nausea and mild fever; PROSTVAC is being developed by Bavarian Nordic 
(Kvistgaard, Denmark). 
 
TroVax® 
TroVax® is being developed by Oxford BioMedica and is based on a vaccine platform utilizing 
the tumor associated glycoprotein (5T4), expressed on several cancer types, including 
colorectal, renal and PC [60]. 5T4 is delivered using the poxvirus vector (modified vaccinia 
virus Ankara (MVA) vector) for delivery. TroVax® does not include a heterologous prime 
boost, and does not include a series of co-stimulatory molecules like PROSTVAC. A phase III 
trial in patients with renal cell carcinoma did not improve survival compared to placebo, but 
subgroup analyses suggested improved survival in patients with a favorable prognosis [61]. 
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The primary advantage of this platform is the novel target antigen, which is broadly 
applicable to multiple tumor types. The major disadvantages are the univalent nature of the 
vaccine construct, as well as a homologous prime-boost regimen. Moreover, in an open-
label Phase II trial in 27 males with progressive disease with TroVax® alone or a combination 
of TroVax® and GM-CSF, was generally well tolerated. Five patients who received TroVax® 
and GM-CSF showed a decline in PSA levels, with none in the TroVax alone group [62].  A 
randomized open-label phase II trial in castration-resistant PC patients, TroVax was 
administered in combination with docetaxel compared to docetaxel alone. TroVax was well 
tolerated in all 25 patients and of the 10 evaluable patients, 6 generated 5T4 specific 
antibody responses Patients in the combined treatment group demonstrated a greater 
median progression-free survival of 9.67 months compared to 5.10 months for docetaxel 
alone [63]. 
 
Ad5-PSA 
A phase I trial of Ad5-PSA with or without gelfoam matrix in patients with PC, was shown to 
be safe (the primary endpoint of the trial), and anti-PSA T cell responses were induced in the 
majority of patients, however an increase rate rise in PSA (PSA doubling time) was noted in 
50 % of patients [64]. A Phase II clinical trial of two separate protocols for patients with 
recurrent or hormone refractory PC were assessed for toxicity, immune responses, and 
changes in PSA levels [65]. In Protocol 1, men with recurrent PC following definitive initial 
treatment for their disease, either received Ad5-PSA alone on days 0, 30, 60, or received 
Ad5-PSA 14 days after the initiation of androgen deprivation therapy, 3 times, 30 days apart. 
In Protocol 2, men with hormone refractory disease received Ad5-PSA alone using the same 
three injection schedules, however Ad5-PSA was suspended in the gelfoam matrix. All of the 
patients in protocol 1 and 67 % of the patients in protocol 2 induced significant anti-PSA T 
cell responses; 64 % of the patients showed an increase in PSA doubling time [65].  
 
AdV-tk including ProstAtakTM 
Intratumoral delivery of Ad vector encoding the herpes simplex virus enzyme thymidine 
kinase (AdV-tk) results in transduced tumor cells becoming susceptible to systemically 
administered prodrugs such as valcyclovir (VCV) or ganciclovir (GCV), which are selectively 
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converted by thymidine kinase to cytotoxic nucleotide analogs [66, 67]. These activated 
drugs can then lyze neighboring proliferating cells via immune activating bystander effects 
[68]. In fact, in a phase I/II clinical trial in 23 advanced PC patients, intraprostatic injections 
of AdV-tk followed by 2 weeks of GCV and prostatectomy 2-4 weeks later, induced a 
significant infiltration of CD8+ T cells within the tumor microenvironment compared to 
control patients [69]. Interestingly, Adv-tk+GCV preferentially induced cytotoxic effects to 
malignant (rather than benign) tissues, although there were no improvements in clinical 
outcome of patients and PSA levels. This lack of clinical efficacy prompted the use of 
combination treatments involving chemotherapy or radiotherapy and Adv-tk+GCV in a 
phase I/II study. Patients with PC received Adv-tk+GCV with radiotherapy and were grouped 
into 3 arms, (i) 29 low-risk PC patients (stage T1-T2a), (ii) 26 high-risk PC patients (stage T2b-
T3) and (iii) 4 PC patients with stage D1 disease. The low-risk and high-risk groups showed 
good locoregional control and stabilization of PSA levels whilst those with D1 disease 
showed no such responses [70].  
 
DNA vaccine formulations 
Plasmid DNA encoding PAP: The pTVG-HP plasmid encoding the PAP protein has been well 
studied in preclinical and clinical settings [71]. In a phase I human clinical trial, pTVG-HP/PAP 
induces PAP-specific interferon (IFN)-gamma (IFN-γ) secreting T cells in males with recurrent 
PC, resulting in increased PSA doubling time [72]. Likewise, a phase I/II trial in patients with 
non-metastatic CRPC injection of pTVG-HP/PAP showed increased PSA doubling time from 
6.5 months to 9.3 months [73]; no adverse reactions were reported. Interestingly, patients 
that did not respond to treatment had high levels of PAP specific IL-10 CD4+ and CD8+ T 
cells prior to vaccination, compared to those who responded with pre-existing IFN-γ and 
granzyme responses to androgen receptor, PSA and PAP [74]. Thus, determining pre-existing 
responses is important prior to PC vaccination trials, and is currently being evaluated in 
ongoing randomized clinical trials (NCT00849121). A list of selected ongoing clinical trials 
related to DNA vaccine are tabulated in Table 1. 
 
Electroporation: Electroporation (EP) makes use of brief electrical pulses that generate 
transient “pores” in the cell membrane, allowing genes (DNA or RNA) to enter the cell’s 
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cytoplasm; antigen expression has been reported to increase up to 1000 fold [75, 76]. The 
use of EP has been translated into human clinical trials. In fact, in a phase I/II dose escalation 
trial, patients with biochemically recurrent PC were either immunized intramuscularly or EP 
with DNA encoding PSMA/tetanus toxin [77]. Both immunization schedules resulted in CD4+ 
and CD8+ T cell responses and increased PSA doubling time compared to baseline, however, 
a significant trend towards higher responses were noted in those treated with EP [77]. EP 
was well tolerated in this study, despite others reporting local pain, inflammation and 
bleeding at the site of injection [78, 79]. A current phase I clinical trial (NCT02514213) [80] is 
underway to determine the safety and immunogenicity of INO-5150 alone (DNA plasmids 
encoding PSA and PSMA) or in combination with INO-9012 (IL-2 plasmid) delivered 
intramuscularly followed by EP in males with biochemically relapsed PC. The trial is expected 
to be completed by mid-2017. It is clear that EP provides an encouraging platform for gene-
based vaccine delivery.  
 
Personalized peptide vaccination 
Personalized peptide vaccination (PPV) uses multiple peptides based on the individuals pre-
existing antibody and/or T cell immunity and has shown promise in boosting such immunity. 
Indeed, in phase I and II clinical trials in patients with CRPC, PPV was well tolerated with 
improved clinical outcomes [81]. In addition, 100 patients with progressive CRPC treated 
with PPV using 2-4 out of 31 candidate peptides showed improved PSA doubling time which 
correlated with antibody and T cell responses, and  improved survival [82]. A phase II trial of 
PPV with or without low-dose cyclophosphamide showed no differences whether 
cyclophosphamide was used, however those who developed anti-peptide immune response 
showed longer improved survival regardless of the treatment arm [83]. Furthermore, a 
phase II trial (UMIN-CTR; 000000959) conducted in HLA-A2+, HLA-A24+ or HLA-A3+ 
asymptomatic patients with CRPC, were either injected with PPV (37 patients) or 
dexamethasone alone (35 patients). Those that received PPV showed significant longer 
progression-free survival than those receiving dexamethasone only (22 months vs 7 
months); the improved survival was also longer in the PPV group (73.9 months vs 34.9 
months) [84]. Moreover, BrightPath Biotherapetics Co. Ltd is sponsoring a phase III, 
randomized, placebo-controlled double blind trial using PPV (ITK-1; 2-4 peptides) in HLA-
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A24+ individuals with docetaxel-refractory mCRPC in Japan (UMIN-CTR; 000011308); 333 
patients will be recruited, antibody, CD8+ T cell responses, frequency of adverse reactions 
and survival rate at 12 months will be assessed [71]. The last patient follow-up is expected 
to be completed by March 2018. 
 
Checkpoint Inhibitors   
Tumor-induced immunosuppressive environment  plays a crucial role in the pathogenesis of 
cancer [85]. Targeting immune checkpoints such as CTLA-4 and PD1/PD-L1 pathways are 
gaining much attention, in the immunotherapy of cancer.  
 
CTLA-4 checkpoint blockade 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) or CD152, is an immune checkpoint receptor 
responsible for suppressing CD8+ T-cell activation. CTLA-4 is also constitutively expressed on 
regulatory T cells where it mediates their immune suppressive effects [86]. Hence, CTLA-4 
blockage could result in broad enhancement of antitumor immune responses, leading to the 
development of monoclonal antibodies that specifically inhibit CTLA-4. Indeed, ipilimumab 
and tremelimumab, are anti-CTLA-4 humanized monoclonal antibodies that have the 
potential to inhibit CTLA-4 ligand-driven immunosuppression. A number of ongoing studies 
are determining the efficacy of ipilimumab in early stage PC. Tables 2 and 3 summarize 
some selected completed clinical trials and the selected ongoing studies of checkpoint 
inhibitors in PC respectively. 
 
PD-1 checkpoint inhibitors  
The programmed cell death protein 1 (PD-1) or CD279, is expressed on activated T cells 
which binds to programmed death ligand 1 or 2 (PD-L1 or PD-L2) on tumor cells, resulting in 
inactivation and death of T cells. The absence of PD-1 expression on T cells has shown to 
significantly delay tumor growth and increase CD8+ T cells within the tumor 
microenvironment in mouse models [87]. Interestingly, tumor biopsies of 7 patients with PC 
noted that 90 % of the infiltrating CD8+ T cells had upregulated cell surface expression of 
PD-1 [88]. Nivolumab, a PD-1 inhibitor approved by the FDA for use in metastatic 
melanoma, showed no objective responses in a phase I trial of 17 patients with mCRPC [89]. 
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However, in another trial, 36 % of those with PD-L1 positive tumors had an objective 
response to treatment. Thus, PD-L1 appears to be a viable biomarker which has significant 
correlation with response to nivolumab [90]. A Phase Ib, dose escalation ongoing study of 
nivolumab (MDX-1106) aims to determine its safety and efficacy in patients with certain 
types of cancer, including PC (NCT00730639).  
 In addition, a phase II trial of combined PD-1 and CTLA-4 blockade in patients with 
mCRPC is being tested (nivolumab and ipilimumab; NCT02601014). Furthermore, 
pembrolizumab, an anti-PD-1 monoclonal antibody is under evaluation as a single agent in 
mCRPC patients previously treated with enzalutamide (NCT02312557) in combination with 
pTVG-HP plasmid DNA vaccine (NCT02499835). CT-011, an anti-PD-1 antibody, is being 
assessed in a phase II trial in combination with sipuleucel-T and low dose cyclophosphamide 
in advanced patients with CRPC (NCT01420965) A phase II study of pembrolizumab in 
combination with enzalutamide in mCRPC patients upon progression on enzalutamide alone 
showed a PSA decline of over 50 % in 20 % of the patients of which some of them remained 
progression-free for up to 60 weeks [91]. 
 
Combination therapy strategy 
Combination therapy is showing greater promise in cancer treatment. In addition to the 
vaccine platforms in early stage PC there is growing interest in combination therapy based 
on significant clinical and preclinical studies. In combination therapies, the addition of 
conventional medicine to the vaccine enhances the therapeutic efficacy through various 
mechanisms. Hormonal combination, chemotherapy combination, immune checkpoint 
inhibitor combination and radiation combination are studied in recent years. A summary of 
clinical trials in combination therapies for the management of PC are shown in Table 4. 
 
Conclusion  
Despite tremendous efforts in the last few decades, there is only one approved vaccine for 
PC with several others in clinical testing. Immune checkpoint inhibitors have shown some 
promise in improving immune based therapies, although it is suggested that single agent 
immune checkpoint inhibitors may have limited clinical utility. But a growing amount of 
preclinical and clinical data suggests that combining immune checkpoint inhibitors, either 
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with other immune checkpoint inhibitors or with therapeutic cancer vaccines, has the 
potential to improve immune response efficacy of vaccines. The improvements in vaccine 
delivery methods are significant to date, and we are well placed with a plethora of 
information and methods to determine the optimal regime for the treatment of mCRPC.  
 
Future Perspectives 
Identification of new PC antigens: Further studies of known PC antigens (MUC1, epidermal 
growth factor receptor, PSMA, prostate stem-cell antigen, platelet derived growth factor, 
metalloproteinase and urokinase plasminogen activator) and identification of new antigens 
will advance vaccination targeting strategies for PC. The six-transmembrane epithelial 
antigen of the prostate (STEAP1) is highly expressed by prostate cancer cells and it is 
thought to be involved in tumor initiation and progression and may be useful in the 
diagnosis of early disease. In addition, PC cells that express STEAP1 results in poorer clinical 
outcomes in patients with PC and is therefore, a potential target for immunotherapy studies 
[92]. In addition, in February 2017 Panacea Pharmaceuticals, Inc. reported that a vaccine 
based on the novel transmembrane protein, human aspartyl-asparaginyl-β-hydroxylase 
(HAAH) used to screen for upregulation of cancer proteins will be evaluated in patients with 
biochemically-relapsed PC. PAN-301-1 (NTC03120832) will be tested in an open-label, 
parallel-designed, multi-center phase I clinical trial to assess its safety and immunogenicity. 
The clinical trial vaccine is delivered via intradermal injection using 3M Drug Delivery 
Systems’ hollow microstructured transdermal system (hMTS). It is delivered as “a quick 
injection” via the hMTS, which is a patient-friendly microneedle delivery solution [93]. The 
estimated completion date is December 2017. Other PC antigens such as, early prostate 
cancer antigen-1 and 2 (EPCA-1, EPCA-2), prostate cancer antigen-3 (PCA-3) and PSA 
isoforms are new and evolving PC antigens to be considered as targets for immunotherapy 
studies. 
 
New modes of PC antigen delivery: Vaccine development faces major challenges both 
technologically and economically. Newer vaccines that are stable, economical, require fewer 
doses and can be administered using needle free systems are a worldwide priority [94]. 
Hence, delivery of vaccines via oral, intranasal, transcutaneous and intradermal routes will 
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decrease the risk of needle-borne diseases and may eliminate the need for trained 
personnel and sterile equipment. As such, the NanopatchTM has revolutionized vaccination 
delivery where vaccine is applied to the skin for 2 minutes and efficient transcutaneous 
antigen delivery ensures [95]. Although there are no studies of such technology for PC, data 
from other settings (influenza vaccine, poliovirus vaccine) are promising. It is speculated 
that in coming years there will be a number of exciting data in the application of the 
NanopatchTM technology in the treatment of various cancers including PC. Additionally, 
various techniques involving new DNA delivery systems (receptor mediated, non-invasive 
ultrasound delivery), adjuvants, micro/nano particles, dendrimers, immunostimulatory 
complexes and transgenic plants are being developed and evaluated. Moreover, miceller 
suspensions, melt in mouth strips, nasal mucosal, polymeric nanoparticles and micro needle 
delivery strategies will take PC treatment options to a new level in coming years [94].  
 
New generation checkpoint molecules: could there be a role in PC: Identification of new 
checkpoint proteins other than CTLA-4 and PD-1/PD-L1, expressed on T cells may further 
revolutionize immunotherapeutic approaches for cancer., B7 group of proteins are cell 
surface proteins expressed on activated antigen presenting cells (DC, macrophages) and 
interacts with either CD28 or CTLA-4 (CD152) on activated T cells. As a result, co-stimulatory 
or co-inhibitory signals are activated. In fact, the interaction between B7-1 (CD80) and B7-2 
(CD86) costimulatory markers on antigen presenting cells with CD28 on T cells results in 
enhanced T-cell activation, whereas, B7-H1 (PD-L1 or CD274, expressed on antigen 
presenting cells and cancer cells) interaction with PD1 (on T cells) inhibits T cell 
functionality. In addition, B7-DC (PD-L2, CD273) also expressed on antigen presenting cells 
binds to PD-1 on T cells leading to their inhibition. The role of other B7 ligands (B7-H3 
(CD276), B7-H4 (VTCN1), B7-H5 (VISTA), B7-H6 (NCR3LG1) and B7-H7 (HHLA2)) are not clear 
[96], although B7-H3 and B7-H4 are implicated in immune-modulatory functions within the 
tumor microenvironment promoting cancer development [97]. TIM3 expressed on Th1 CD4+ 
and CD8+ T cells (but not on Th2 cells) regulates the activation of macrophages. TIM3 also 
stimulates cancer progression, maintaining the tumor immunosuppressive 
microenvironment status by inducing T cell suppression [98]. Over-expression of TIM3 on 
infiltrating CD4 and CD8 T cells within the tumor microenvironment and on peripheral blood 
T cells of PC patients, correlates with advanced disease stage [99]. In various preclinical 
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models, inhibition of both PD-1 and TIM3 enhanced antitumor immune responses, support 
TIM3 as a new potential target for immunotherapy studies [100]. Understanding the role of 
B7 proteins and TIM3 may prove useful checkpoint inhibitors in future preclinical and 
clinical studies in the management of PC.  
 
Executive summary 
• The first autologous cellular immunotherapy approved by the FDA, sipuleucel-T 
shows promising results in patients with PC 
• GVAX, PROSTVAC, TroVax, Ad5-PSA, AdV-tk including ProstAtakTM and tumor cells 
transfected with mRNA are emerging gene based strategies for PC 
• DNA vaccine formulations including plasmid DNA encoding PAP or electroporation 
delivery induce immune responses in patients with PC 
• Personalized peptide vaccination (PPV) uses multiple peptides based on the 
individuals pre-existing antibody and/or T cell immunity and has shown promise in 
boosting such immunity.  
• The combination of immune checkpoint inhibitors and therapeutic cancer vaccines is 
of particular interest as it has the potential to increase efficacy compared to single 
agent immune checkpoint inhibition with minimal added toxicity. 
• Identification of new checkpoint proteins other than CTLA-4 and PD-1/PD-L1 has 
revolutionized immunotherapeutic approaches for prostate cancer treatment. 
• Phase III Clinical trial (NCT02111577) is recruiting patients for the study of DCVAC 
added to standard chemotherapy for men with mCRPC and the primary objective of 
the study is to evaluate overall survival. In this study DC will be used as biological 
intervention and docetaxel and taxotere  as chemotherapeutic agents. 
• A phase II clinical trial is recruiting patients for the study of PROSTVAC in 
combination with nivolumab and /or ipilimumab in males with PC (NCT02933255). 
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Table 1: Summary of some selected ongoing/completed clinical trials utilizing DNA vaccines for PC 
Intervention Phase & trial ID Objectives of 
the study 
Outcome/study 
completion date 
Ref 
PAP: Sipuleucel-T with or 
without 
pTVG-HP DNA booster 
vaccine 
Phase II 
(NCT01706458) 
 
Measurement of 
immune 
response 
 
 
Ongoing/July 
2021 
[101] 
PAP Plus rhGM-CSF with or 
without pTVG-HP  
Phase II 
(NCT01341652) 
 
Metastasis-free 
survival 
Ongoing/March 
2020 
[102] 
PROSTVAC V/F with or 
without 
GM-CSF 
Phase III 
(NCT01322490) 
 
Overall survival 
(OS) 
Ongoing/June 
2018 
[103] 
  
Flutamide with or without 
PROSTVAC/TRICOM 
 
Phase II 
(NCT00450463) 
 
 
Time to 
treatment 
failure 
 
Study completed 
in June 2017. No 
results have been 
posted 
 
 
[104] 
Adenovirus/PSA Vaccine  Phase II 
(NCT00583024) 
 
PSA-doubling 
time response 
Ongoing/July 
2017 
[105] 
PSA: Adenovirus/PSA with or 
without ADT 
Phase II 
(NCT00583752) 
PSA-doubling 
time response 
Ongoing/July 
2017 
[105] 
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Table 2: Summary of completed trials of checkpoint inhibitors alone or in combination with other 
agents in prostate cancer 
Study compound Study details Results Reference 
Ipilimumab A Phase II study to evaluate OS, in 
chemotherapy naive mCRPC 
patients 
Completed, No results 
available 
NCT01057810 
Ipilimumab  A phase II study to evaluate the 
Immunological variables 
measurements in  patients with 
prostate cancer before radical 
prostatectomy 
Completed, No results 
available 
NCT01194271 
Ipilimumab A phase III study to determine if 
asymptomatic or minimally 
symptomatic patients with mCRPC 
who have not received 
chemotherapy live longer when 
treated with ipilimumab than 
those treated with a placebo 
No significant difference 
in OS between treatment 
and placebo [28.6 months 
vs 29.73], PFS time was 
more in treatment group 
(5.59 months) than 
placebo (3.81 months) 
NCT01057810 
Ipilimumab with or 
without Radiation 
therapy (RT) 
A phase I/II study to assess safety 
of ipilimumab alone or with RT in 
patients with mCRPC with or 
without prior chemotherapy  
PSA decline >50%:16% [106] 
Ipilimumab plus ADT A  phase II study to compare a 
single dose of ipilimumab with ADT 
versus ADT alone in patients with 
mCRPC 
Patients treated with 
ipilimumab plus ADT were 
more likely to have 
undetectable PSA levels 
by 3 months (55% vs 38%) 
[107] 
Ipilimumab with or 
without Docetaxel 
A  phase II study to compare the 
co-administration of ipilimumab 
alone or with docetaxel in 
chemotherapy-naive patients with 
mCRPC 
Co-administration of 
docetaxel did not improve 
the activity of ipilimumab 
[108] 
Ipilimumab following 
RT 
A randomized, phase III trial to 
compare ipilimumab vs placebo 
following RT in patients with 
mCRPC previously treated with 
docetaxel 
The primary objective was 
not achieved [OS: 11.2 
months vs 10 months; 
p=0.053]. Improvement 
PFS [4 months vs 3.1 
months; p<0.0001] and in 
[109] 
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PSA response [13.1 % 
vs 5.2%] 
Ipilimumab plus 
PROSTVAC 
A phase I dose-escalation trial to 
assess the  safety of ipilimumab 
with and PROSTVAC in patients 
with mCRPC 
The level of PSA was 
decreased by 58% 
[110] 
Ipilimumab plus 
GVAX 
A phase I dose-escalation trial 
using one GVAX priming dose 
along with ipilimumab in patients 
with mCRPC 
The level of PSA declined 
>50% 
[111] 
Ipilimumab plus GM-
CSF 
A phase I dose-escalation trial to 
assess the  safety of ipilimumab 
with a fixed dose of GM-CSF 
The level of PSA was 
decreased >50% 
[112] 
Tremelimumab plus 
ADT 
A phase I dose-escalation trial to 
assess safety of tremelimumab in 
combination with bicalutamide 
There was no significant 
increase in PSA doubling 
time 
[113] 
OS, overall survival; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific 
antigen; ADT, androgen deprivation therapy; HR, hazard ratio; PFS, progression-free survival; RT, 
radiotherapy; GMCSF, granulocyte-macrophage colony-stimulating factor. 
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Table 3:  Summary of selected ongoing checkpoint inhibitors in patients with mCRPC 
Study compound and 
study Phase 
Primary endpoints Trial Status Clinicaltrials.go
v ID 
Nivolumab and/or 
Ipilimumab, phase I/II 
To evaluate changes in T-
cell infiltration in the 
tumor after neoadjuvant 
treatment 
Estimated study 
completion date 
August 2021 
NCT02933255 
Ipilimumab/early 
phase I 
To assess the impact of 
Ipilimumab on T cell 
responses to new antigens 
Active, estimated 
study completion 
date, August 2018 
NCT02113657 
Ipilimumab plus AA, 
phase I/II 
PFS and safety Active, estimated 
completion date 
September 2017 
NCT01688492 
Ipilimumab with 
Nivolumab, phase II 
To assess the changes in 
PSA response (> 50% PSA 
decline) using PCWG2 
guidelines 
Active, estimated 
completion date 
February 2019 
NCT02601014 
Ipilimumab with 
Degarelix, phase II 
To evaluate an 
undetectable PSA at 12 
and 20 months (weeks 52 
and 84, respectively) from 
the start of treatment 
among patients with non-
castrate (> 150 ng/ml) 
levels of testosterone.  
Active, estimated 
completion date 
December 2018 
NCT02020070 
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Table 4: Selected combination strategy in clinical trial phases for the management of PC 
Title Clinical trial ID 
number and 
phase 
Objective & present status of trial 
Sequencing of 
Sipuleucel-T and ADT in 
males with non-
metastatic PC 
NCT01431391, 
phase II 
To determine whether ADT started before or after 
sipuleucel-T leads to a better immune system response. 
Evaluation of the safety of sipuleucel-T treatment, 
immune system responses over time, the characteristics 
of sipuleucel-T, and changes in PSA values over time. 
Study completed. Immune response was more in 
Sipuleucel-T followed by ADT than ADT followed by 
Sipuleucel-T in regards to T cell stimulation 
Enzalutamide in 
combination with PSA-
TRICOM in patients with 
non-mCRPC 
NCT01875250, 
phase II 
To compare the safety and effectiveness of 
enzalutamide with and without vaccine therapy for 
advanced PC. Estimated completion date January 2019 
Enzalutamide +/- 
vaccine therapy for 
advanced PC 
NCT01867333, 
phase II 
A comparative study on the safety and effectiveness of 
enzalutamide with and without vaccine therapy for 
advanced PC. Estimated completion date January 2019 
Sipuleucel-T +/- 
radiation therapy in 
treating patients with 
hormone-resistant 
metastatic PC 
NCT01807065, 
phase II 
A feasibility study, based on the % able or willing to 
receive all 3 infusions of sipuleucel-T immunotherapy, 
when combining sipuleucel-T with radiation therapy to a 
single site of metastasis delivered one week prior to 
beginning of sipuleucel-T therapy. Estimated completion 
date January 2018 
 
Sipuleucel-T and 
Stereotactic Ablative 
Body Radiation in 
mCRPC patients. 
NCT01818986, 
phase II 
To evaluate the synergistic effects of immunotherapy 
and  stereotactic ablative body radiation which is 
expected to improve the treatment outcome for mCRPC 
Estimated completion date December 2018 
 
Vaccine therapy with 
pembrolizumab in 
treating patients with 
hormone-resistant, 
metastatic PC 
 
NCT02499835, 
phase I and II 
A randomized pilot trial to study vaccine therapy and 
pembrolizumab in treating patients with PC that do not 
respond to treatment with hormones (hormone-
resistant) and have spread to other places in the body 
(metastatic). Monoclonal antibodies, such as 
pembrolizumab, may find tumor cells and help kill them. 
Giving pTVG-HP plasmid DNA vaccine and 
pembrolizumab may kill more tumor cells. Estimated 
completion date April 2019 
 
